Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share CapitalTOULOUSE, France, October 02, 2026--Regulatory News: ABIONYX Pharma (Paris:ABNX):
- Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that data from the Company’s lapemelanotide zapixetar (also known as [²¹²Pb]VMT01) program have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting & Pre-Conference Programs taking place November 4 to 8, 2026, in Phoenix, Arizona. SITC plans to release further details for regular abstracts on November 3, 2026.
- Pfizer Inc.Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental VitiligoCompanies: PfizerNEW YORK, October 02, 2026--Pfizer Inc. (NYSE: PFE) today presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO® (ritlecitinib) as a once-daily oral treatment across a wide range of disease extent.
- Dyno Therapeutics, Inc.Dyno Therapeutics Presents New Multi-Mechanism Muscle Capsid Data at the 31st International Congress of the World Muscle SocietyWATERTOWN, Mass., October 02, 2026--Dyno Therapeutics presents new multi-mechanism muscle capsid data at the 31st international Congress of the World Muscle Society
- BioMarin Pharmaceutical Inc.BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual CongressLong-term data reinforce durable efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe disease — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data evaluating the efficacy and safety of POMBILITI® (cipaglucosidase...
- MarketsandMarketsClinical Trial Supplies Market worth $8.95 billion by 2031 - Exclusive Report by MarketsandMarkets™According to MarketsandMarkets™, the Clinical Trial Supplies Market is projected to reach USD 8.95 billion by 2031 from USD 5.60 billion in 2026, at a CAGR of 8.9% during the forecast period. Browse 420 market data Tables and 50 Figures...
- CRISPR Therapeutics AGCRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company’s Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune disease, will be presented at the American College of Rheumatology (ACR) Convergence 2026.
- Aulos Bioscience Announces Presentations of Promising Phase 1/2 Data for Imneskibart With Checkpoint Inhibitors in Non-Small Cell Lung Cancer and Melanoma at SITC 2026 Annual MeetingLARKSPUR, Calif., October 02, 2026--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), today announced that two presentations of new data from its ongoing Phase 1/2 study of imneskibart will be featured at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
- Pheast Therapeutics to Present Preclinical Data on PHST001, a First-in-class Antibody Targeting CD24, at the Society for Immunotherapy of Cancer (SITC) 2026 Annual MeetingREDWOOD CITY, Calif., October 02, 2026--Pheast Therapeutics, a clinical-stage biotechnology company advancing next-generation targeted therapies for cancer, today announced an upcoming poster presentation of preclinical data on PHST001 at the 41st Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place from November 4-8 in Phoenix, AZ. PHST001 is a first-in-class anti-CD24 macrophage checkpoint inhibitor designed to restore immune recognition in the tumor microenvironment and is
- Agenus Inc.Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026LEXINGTON, Mass., October 02, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona.
- Rigel Pharmaceuticals, Inc.Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and...
- Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century's iPSC-derived islet replacement therapy for type 1 diabetes